According to the STEP clinical trials for semaglutide 2.4 mg (Wegovy), diarrhoea was reported in approximately 20-30% of participants receiving the medication
Gastrointestinal symptoms: Some peptides, especially GLP-1 receptor agonists such as semaglutide or tirzepatide, can slow digestion, which may lead to nausea, vomiting, diarrhea, or constipation
Collombat, P
Bioactive Plant Compounds Green Tea Extract (EGCG) Epigallocatechin gallate (EGCG), the primary catechin in green tea, has shown promise for enhancing GLP-1 activity
Contraindications, Cautions and Common Mistakes Standard injectable contraindications apply: pregnancy and breastfeeding, active infection at the treatment site, known allergy to any disclosed ingredient, and caution around anticoagulant use given the bruising risk